Filana Therapeutics, Inc. Common Stock (FLNA) Stock Price
FLNAStock
$0.70
Market Cap$33.98M
P/E—
PEG Ratio1.62
Div yield—
Beta1.46
FLNA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-65.66%
Price vs S&P 500 (4W)-3.54%
PEG Ratio1.62
VGM Score58.48
FLNA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.23 | -$0.18 | +20.00%(+$0.05) | |
| Q1 2026 | -$0.23 | -$0.21 | +8.70%(+$0.02) | |
| Q4 2025 | -$0.30 | -$0.26 | +13.33%(+$0.04) | |
| Q3 2025 | -$0.27 | -$0.22 | +18.52%(+$0.05) | |
| Q2 2025 | — | -$0.92 | — |
FLNA Analyst Recommendations
Dec 2025
Jan 2026
Feb 2026
Mar 2026
4.00
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
FLNAFilana Therapeutics, Inc. Common Stock | A | — | D | 0.8x | — | — | — | $0.70 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Filana Therapeutics, Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.